WHITEHOUSE STATION, N.J., Nov. 10, 2011 – Merck (NYSE:MRK), known outside the United States and Canada as MSD, today is hosting a R&D and Business Briefing. "Innovation is the centerpiece of our growth strategy at Merck," said Kenneth C. …
WHITEHOUSE STATION, N.J. & CAMBRIDGE, Mass., Oct. 5, 2011 -- Merck (NYSE:MRK), known outside the United States and Canada as MSD, and ARIAD Pharmaceuticals, Inc., (NASDAQ:ARIA), today announced that the U.S. Food and Drug Administration (FDA) has …
SAN DIEGO, Sept. 19, 2011 - New clinical and pre-clinical data on Merck's odanacatib, an investigational cathepsin K (cat-K) inhibitor for the treatment of osteoporosis in post-menopausal women, were presented at the 33 rd Annual Meeting of The …
BERLIN, March 31, 2011 - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease …
BERLIN, March 31, 2011 - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, reported that final results from a Phase III study of VICTRELIS ™ (boceprevir), its investigational oral hepatitis C protease inhibitor, added to …
WHITEHOUSE STATION, NJ, March 24, 2011 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved an expanded age indication for ZOSTAVAX ® (Zoster …
WHITEHOUSE STATION, N.J., March 9, 2011 -- Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the New Drug Application (NDA) for SAFLUTAN ® (tafluprost), Merck's investigational preservative-free …
WHITEHOUSE STATION, N.J., March 7, 2011 - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that several new data analyses from Phase III studies of VICTRELIS ™ (boceprevir), its investigational oral …
02 days 04:03:07
